✦ LIBER ✦

A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): a study of the Umbrian Lung Cancer Group

✍ Scribed by Lucio Crino; Maurizio Tonato; Samir Darwish; Maria L. Meacci; Enrichetta Corgna; Francesco Di Costanzo; Franco Buzzi; Giovanni Fornari; Emilio Santi; Enzo Ballatori; Carla Santucci; Stephen Davis

Publisher: Springer
Year: 1990
Tongue: English
Weight: 485 KB
Volume: 26
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf02940294

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase I trial of ifosfamide, mesna, an

A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer a cancer and leukemia group B study

✍ Stephen L. Graziano; James E. Herndon II; Frederick Richards II; Santo Difino; C 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 737 KB

Mitogauzone, cisplatin, and vinblastine

Mitogauzone, cisplatin, and vinblastine in advanced non-small cell lung cancer: A Southwest Oncology Group study

✍ Robert Chapman; John Crowley; Joel G. Lucas; Ben Lin Hom; Robert B. Livingston; 📂 Article 📅 1993 🏛 Springer US 🌐 English ⚖ 146 KB

A randomized study of two vindesine plus

A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer

✍ R. Rosell; A. Abad-Esteve; I. Moreno; A. Barnadas; J. Carles; C. Fernandez; N. R 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 726 KB

A phase I pharmacokinetic study of bexar

A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC)

✍ Heather A. Wakelee; Gary Middleton; David Dunlop; Rodryg Ramlau; Natasha Leighl; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 284 KB

Increasing dose intensity of cisplatin-e

Increasing dose intensity of cisplatin-etoposide in advanced nonsmall cell lung carcinoma : A Phase III randomized trial of the Spanish lung cancer group

✍ Albert Font; Alfredo J. Moyano; Jose M. Puerto; Alejandro Tres; Carlos Garcia-Gi 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

## Background: The authors designed this randomized, controlled trial to assess whether dose intensification of a cisplatin-etoposide combination (pe), achieved by shortening the interval between chemotherapy cycles, would improve response rate and survival. the maximum tolerated dose of pe was adm

Platinum-based combination chemotherapy

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: A randomized phase II trial of the cancer and leukemia group B

✍ Green, Mark R. ;Kramar, Andrew ;Schilsky, Richard ;Stoopler, Marc ;Zimmer, Bonni 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 504 KB

## Abstract The Cancer and Leukemia Group B (CALGB) utilized a randomized phase II trial design to evaluate two cisplatin‐based combinations, cisplatin‐cytarabine (ara‐C) and cisplatin‐vinblastine, in 151 patients with advanced non‐small cell lung cancer. Patients entered on study had not received